Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sam D. Molyneux, Marco A. Di Grappa, Alexander G. Beristain, Trevor D. McKee, Daniel H. Wai, Jana Paderova, Meenakshi Kashyap, Pingzhao Hu, Tamara Maiuri, Swami R. Narala, Vuk Stambolic, Jeremy Squire, Josef Penninger, Otto Sanchez, Timothy J. Triche, Geoffrey A. Wood, Lawrence S. Kirschner, Rama Khokha
Published in Volume 120, Issue 9
J Clin Invest. 2010; 120(9):3310–3325 doi:10.1172/JCI42391
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 9
Evidence for a molecularly distinct PRKAR1A-low subset of human OSA.

(A) PRKAR1A expression in 54 human OSAs, ranked low to high, with the lowest and highest 25% indicated. Response to chemotherapy is indicated by colored blocks. (B) The normalized expression level of PRKAR1A was compared between responders and nonresponders. Boxes depict IQR; lines within represent the median; whiskers denote maximum and minimum values. (C) Unsupervised analysis of human OSAs using hierarchical clustering. The cAMP/PKA/skeletal gene set (human orthologs) was used and samples were annotated according to low or high expression of PRKAR1A and PRKACA (below heat map).